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(SP) officially replaced chloroquine
(CQ) as first-l ine treatment in malaria
control in South Africa because of
concerns about chloroquine resist-
ance'. In northern KwaZulu-Natal
medical officers at Mosvold, Manguzi,
Bethesda and Mseleni hospitals used
SP combined with CQ because of
perceived benefit of chloroquine,
whereas the Malaria Control
Summary- i \
Objective.
To assess the failure rate of the present first line treatment regime for





Ndumo Clinic, Ingwavuma District, South Africa, October 2000
Study Group.55 patients presenting to Ndumo clinic with uncomplicated
malaria and malaria trophozoites visible on thin film.
Main outcome measures:
Trophozoite count on thick film at day 14.
Results.
l5 out of 37 patients who returned for follow-up still had trophozoites
on thick film. Symptoms of most patients at day 0 and day l4 were mild,
parasite counts before and after treatment were low, and trophozoites
were atypical.
Conclusions.
There appears to be an unacceptably high day 14 failure rate with the
combination of sulfadoxine/pyrimethamine and chloroguine.The mildness
of symptoms, low parasite counts and atypical trophozoites suggest
immunity to falciparum malaria amongst the local population. With few
antimalarials to chose from, the difficult question as to future treatment
of uncomplicated malaria arises.
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Programme used SP alone to treat
both self-presenting patients(passive
cases) and cases detected through
active surveil lance. From January to
April 2000 an in vivo study' of the
efficacy of SP conducted by the
National Malaria Research Pro-
gramme at Ndumo Clinic, Ingwavuma
District, KwaZulu-Natal, South Africa,
showed failure of SP treatment in ac
least 6 |.2% patients by the end of 28
days.The 14 day failure rate was 50%
of recruited (63/ 125), but 73%(63186)
of those who returned. In the
absence of immediately available new
first l ine anti-malarial drugs for
uncomplicated malaria, SP combined
with CQ was adopted as first l ine
treatment for uncomplicated malaria
th roughout KwaZulu-Natal.
There have been few studies of SP
combined with CQ. In a Cochrane
reviewo Mclntosh concluded that in
areas where chloroquine is sti l l  effec-
tive, chloroquine in combination with
SP may make people feel better faster
and improve sustained parasite clear-
ance. Bojang et als, in a trial of SP
alone versus SP with CQ in Gambian
children, found SP with CQ to be
more effective symptomatically, but
no difference in parasite cure rate.
There has been a dramatic increase in
malaria incidence in KwaZulu-Natal
and South Africa since 1996. For
example, at Ndumo clinic, Ingwavuma
District, South Africa, (a satellite clinic
of Mosvold Hospital, covering an area
with the highest incidence of malaria
in South Africa), cases detected
increased from 637 in 1995, to 2 972
in 1998, and 17 420 in 1999. From
January to May 2000 alone, 21 352
cases were detected at the clinic,
requiring the aid of the South African
Defence Force. In 1995, in South
Africa, there were 5 992 notified
cases of malariat whereas from
January to May 2000 there were 36
717 notified malaria cases'.With such
large numbers of patients being treat-
ed, an audit of the failure rate of the
treatment regime was desirable. A
WHO protocol' for assessment of
therapeutic efficacy of antimalarial
drugs requires follow-up of patients
on at least days 0,1,2,3,7 and l4.This
requires substantial resources, and
preventing patients dropping out is
difficult. Department of Health
Guidelines' recommend that a follow-
up blood smear be taken after 2-3
weeks. This has not been implement-
ed routinely in northern KwaZulu-
Natal, due to numbers of patients and
limited laboratory facilities. Applying
the guidelines in the form of a single
14 day follow-up of a sample of
patients was chosen as a quick and
simple audit of the of the regime of
SP and CQ combined, deviating l itt le
from routine management.
The interval between date of infec-
tion with plasmodium falciparum and
the time when parasites are
detectable in the blood (the pre-
patent period) is 9- l0 daysro. This
means that there is an increasing pos-
sibility that parasites present after day
14 may be due to reinfection rather
than drug resistance. After 14 days
techniques such as polymerase chain
reaction are needed to distinguish
between resistant malaria and reinfec-
tion. A blood film at day fourteen
would be expected to provide useful
information regarding the combined
early treatment failure (ETF) and late
treatment failure (LTF), as well as the
proportion of patients showing ade-
quate clinical response (ACR) to the
therapeutic regime (see table l).
Study Population and Methods
Pre-study calculation of sample
size
Sample size was calculated according
to statistical considerations in a
World Health Organisation protocol'
using a system called the Double Lot
Quality Assurance method. This sys-
tem is designed to allow identif ication
of communities in which prevalence
of resistance is above a critical level,
with small sample sizes. Taking a 25%
failure rate to be definitely unaccept-
able, but l0% or less definitely
acceptable, a sample size of 42 is suf-
ficient to detect a 25% failure rate
with a probability of 0.05 of erro-
neously concluding a failure rate of
less than l0% (type I error), whilst
being 80% sure of not erroneously
concf uding there to be a 25% failure
rate when it is really less than l0%
(type 2 error). Using this method and
applying the given thresholds, 5 or
less treatment failures could be con-
sidered acceptable, but more than 5
would be unacceptable. To allow for
drop-outs,55 patients were invited to
return for follow-up.
Table l: Classification fTherapeutic Responses
Early treatment failure
(ErF)
Patient develops one of the following conditions
during the first three days of follow-up:
. Development of danger signs or severe malaria
on Day |, Day 2 or Day 3, in the presence of
parasitaemia;
. Axillary temperature> 37.5"C on Day 2 with par-
as i taemia>Day0count ;
. Axillary temperature > 37.5"C on Day 3 in the
presence of parasitaemia;
. Parasitaemia on Day 3 > 25 % of count on Day 0.
Late treatment failure
(LrF)
Patient develops one of the following conditions
during the follow-up period from Day 4 to Day 14
. Development of danger sings or severe malaria in
the presence of parasitaemia on any day from
Day 4 to Day 14, without previously meeting any
of the criteria of early treatment failure;
. Axillary temperature > 37.5'C in the presence of
parasitaemia on any day from Day 4 to Day 14,




Patient shows one of the following conditions
during the fol low-up period (up to day l4):
. Absence of parasitaemia on Day l4 irrespective
of axillary temperature, without previously meet-
ing any of the criteria of early or late treatment
failure;
. Axillary temperature < 37.5"C irrespective of the
presence of parasitaemia, without previously
meeting any of the criteria of early or late treat-
ment failure.
In October 2000, over six working
days, 89 self-presenting patients at
Ndumo clinic, diagnosed as suffering
malaria by positive immunochromo-
graphic test (KAT-Quick Malaria
Rapid Test for Plasmodium falciparum
- Cape Biotech (Pty) Ltd ), were
asked if they would be prepared to
return for a two week check.
Patients were assessed by a medical
officer, and those with severe or com-
plicated malaria, pregnant women,
patients aged under | 6 years and
patients treated for malaria during
the previous two weeks were exclud-
ed from the audit. Children under l6
were excluded so that all patients
could receive exactly the same
regime for simplicity, while other
exclusions on clinical grounds were
treated in hospital with quinine,
according to standard practice. 87189
patients were willing to return for fol-
low-up at 14 days. Previous experi-
ence had shown that patients with
more strongly positive rapid tests
were more likely to have visible para-
sites on thin fi lm, so there was a
selection tendency to invite those
with more strongly positive rapid
tests.Thick and thin blood fi lms were
taken, and thin fi lms read immediately
after staining. Thick fi lms required 24
hours to dry and so could not be
read immediately. Only those who
were thin film positive were asked to
return for repeat blood smears at
two weeks, to ensure that a compari-
son of parasite counts could be
made.
The fi lms were examined by a med-
ical technologist from KwaZulu-Natal
laboratory services. Thin fi lms were
air-dried, f ixed with methanol, stained
with l0% Giemsa rinsed with tap
water, air-dried and examined using a
l00x o i l  ob ject ive.Thick b lood f i lms
allowed 24 hours to dry and then
were stained with l0% Giemsa (5ml
Giemsa diluted with 45ml phosphate
buffer) for l0 minutes, rinsed with tap
Table ll.' Treatment regime for uncomplicated malaria at Ndumo Clinic
Sulfadoxine S00mg/pyrimethamine 25mg (fansidar - Roche) 3 tablets
Chloroquine sulphate 200mg (nivaquine - Rhone-Poulenc Rorer) 4 tablets
Followed by
Chloroquine sulphate 200mg 2 tablets per day for 3 days to take at home
Table fll: Results of follow-up smear at Ndumo Clinic, Oct 2000
Patients enrol led
Day l4 thick film negative
Day l6 thick film negative
Day l7 thick film negative
Total negative follow-up
Day l4 thick f i lm posit ive
Day l7 thick f i lm posit ive











water, air-dried and observed with
l00x oil objective. Malaria parasites
were counted in conjunction with
300 white cells. The number of para-
sites was multiplied by 25 to estimate
the number of parasites per
microlitre of blood. Patients were
given the usual adult treatment for
uncomplicated malaria at Ndumo
Cl in ic ,which is  g iven in table l l .
All patients were told to return
immediately should their condition
deteriorate.
The Medical Superintendent of
Mosvold Hospital accepted the study
as an audit of current, practice
through the application of Depart-
ment of Health guidelines.
,, ,, ' , i . RgSultSR'i:,
56 patients had parasites visible on
thin fi lm. One patient left the clinic
before the result of his thin smear, so
55 were asked to return for follow-
up blood smears at day 14. Two
patients who were negative at follow-
up had been inadvertently retreated
with SP and CQ at, Ndumo clinic
without medical referral; one received
repeat treatment after seven days,
and the other after | | days. The
results may be summarised as in Table
ilt:
l f i t were assumed that all those who
failed to return were parasite nega-
tive, and that the failure rate was real-
ly 15155(27%) which is the best possi-
ble scenario for the regime, then the
95% confidence interval for the fol-
low-up failure rate would be between
15% and 39%.
| 0 patients (one being the day | 7
result) with parasites on thick fi lm at
follow-up showed a raised parasite
count compared to day 0, while in 5
patients the parasite count was
decreased.
Parasite counts were low: 49155
patients had day 0 parasitaemia of less
than | 000 trophozoites per
microlitre. 6155 day 0 parasite counts
were between 1000-2000, the highest
count being I 575 trophozoites per
microlitre. The highest follow-up
count was a Patient at day 14 with a
count of | 500 trophozoites per
microlitre. Thin films examined while
the patient waited, only detected par-
asites in two follow-up patients.
The trophozoites in all but one
patient were noted to be atypical, and
not the typical plasmodium falciparum
ring forms. Gametocytes were seen in
one patient. Neither the patient with
typical ring forms, nor the patient
with gametocytes returned for fol-
low-up.
The mildness of the presenting symp-
toms was notable. Of 76 patients ini-
tially considered for audit, whose
temperatures were recorded in trial
notes,59 (78%) patients were apyrex-
ial with temperatures of 37"C or less.
Only one patient had a temperature
above 37.9"C and that patient was
admitted for treatment with quinine.
Of 33 follow-up temperatures
recorded, only one patient had pyrex-
ia, with a temperature of 37.2"C.
Of interest is the observation that
although 32/87 patients were exclud-
ed from the audit on account of being
thin smear negative, thick smears only
failed to see parasites on 2/76 thick
smears (thick smears of patients not
t . Katzenellenbogen JM, Joubert J,
Abdool Karim SS. Epidemiology: A
Manual for South Africa. Oxford
University Press Southern Africa
1997 .  p .7 l
Sharp BL, le Sueur D. Malaria in South
Africa - the past, the present and
selected implications for the future.
S Afr Med J 1996;86( l):83-89
BredenkampBLF, Sharp BL, Mthembu
SD, Durrheim DN, Barnes Kl. Failure
of Sulphadoxine-pyrimethamine in
treating Plasmodium fulciparum
malaria in KwaZulu-Natal Province.
S Afr Med J 200l;9 | (l l):970-972




(Cochrane Review). In: The Cochrane
invited back were not kept for counts
at the start of the audit).
rw Gonclusionsre
Although l8/55 (33%) patients were
lost to follow-up, this audit demon-
strated that 15155 (27%) patients
failed to clear parasites at 14 days
with SP/CQ combined. Despite the
patients lost to follow-up, l5 failures
from 42 or less patients well exceeds
the 5 failures which would be consid-
ered the acceptable upper limit,
assuming a 25"/" failure rate to be
unacceptable, but less than l0%
acceptable. As the proportion of fail-
ures amongst those who did return
was 15/37 (41%), it is likely that the
true failure rate is higher than 27%,
which would be considered by most
authorities to be unacceptably high,
and necessitate the introduction of
alternative fi rst-line antimalarial ther-
apy. Since completion of this audit
Coartem-' tablets (20mg artemether
and l20mg lumefantrine - Novartis
South Africa (PTY) Ltd) have been
introduced as the recommended
treatment for uncomplicated malaria
in KwaZulu-Natalrr.
The mildness of the symptoms, low
parasite counts, and unusual appear-
ance of trophozoites raise the ques-
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